FUJIFILM INITIATES A PHASE I CLINICAL TRIAL OF ANTI-CANCER DRUG FF-10101 IN THE UNITED STATES IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

By medical service

FUJIFILM INITIATES A PHASE I CLINICAL TRIAL OF ANTI-CANCER DRUG FF-10101 IN THE UNITED STATES IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) .   


FUJIFILM Corporation (President: Kenji Sukeno) announced the commencement of a Phase I clinical trial of its anti-cancer drug FF-10101 in the Unites States in patients with relapsed or refractory acute myeloid leukemia (AML).

 

Currently, the number of estimated new AML patients is around 20,000 in the United States each year. Press Center | Fujifilm USA

 

http://www.fujifilmusa.com/press/news/display_news?newsID=881224

More from tokioX :

  1. Japan: anti-influenza drug, ‘Avigan Tablet’ recommended: Fujifilm Development
  2. Shimadzu Corporation: Analysis of correlation between matcha and amyloid β content in the brain
  3. 🔬Hitachi to begin demonstration test on cancer test using urine specimen
  4. 🏥Toyota Tsusho、Entry into the Subcontracted Clinical Laboratory Business in Indonesia through Joint Venture with Southeast Asia’s Largest Pharmaceutical Manufacturer
  5. FUJIFILM SECURES DIN-PACS IV CONTRACT FROM U.S. DEPARTMENT OF DEFENSE
  6. Japan 5-Year Cancer Survival Rate at 65.2 Pct .
  7. 富士フイルム、デジタル胸部温熱療法システムをモントレーのマンモグラフィセンターに導入